Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaptesed pegol + Pembrolizumab in Metastatic Colorectal and Pancreatic Cancer
NCT03168139Phase 2Completed
- Sponsor
- TME Pharma
- Start
- Apr 2017
- Primary completion
- Mar 2020
- Modality
- Polymer-based Nanoparticles, RNA Aptamers, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaptesed pegol in metastatic colorectal cancer (mCRC), sponsored by TME Pharma. Primary endpoints: Pharmacodynamic Effects of Monotherapy up to 14 days and Safety of Combination Therapy up to 24 months. Started Apr 2017; status: completed.
02
Drugs
olaptesed pegol
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03168139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03168139.